Rheumatology

Back to articles

Non-TNFi biologics may be more effective than TNFis for rheumatoid arthritis

KEY POINT

A recent study published in Rheumatology showed that patients with rheumatoid arthritis (RA) had better treatment outcomes when given nontumor necrosis factor inhibitor (TNFi) biologics, particularly tocilizumab (Actemra—Genentech) and rituximab, rather than TNFis.